In this study, we analyzed in a retrospective cohort of 62 breast cancer patients the impact of obesity and tumoral apelin expression on response to neoadjuvant chemotherapy. The gene discussed is APLN; the disease is obesity due to melanocortin 4 receptor deficiency.